Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 50,925

Document Document Title
WO/2020/076246A1
The invention is about a herbal composition that intends to decrease the symptoms of chronic and infectious prostate inflammation such as pain, distress and thamuria; and contains epilobium parviflorum, urtica dioca, arctostaphylos uva-u...  
WO/2020/073088A1
Provided herein are methods for treating or preventing inflammation, inflammatory conditions and autoimmune conditions, optionally of the gastrointestinal tract, urinary tract, skin, nails or joints. Also provided are methods of treating...  
WO/2020/077338A1
Compositions and method for reducing the concentration of uremic toxins in the body of a patient suffering from some degree of kidney failure are disclosed. The methods can be used to delay the need for conventional dialysis treatment or...  
WO/2020/077267A1
Disclosed are methods for predicting, inhibiting, and treating chronic kidney disease (CKD) in a subject that that is preparing to undergo a liver transplant. The methods may include detecting a protein biomarker in a serum sample from t...  
WO/2020/075764A1
Provided is a compound that inhibits the activity of TRPV4, and that is useful in the prevention or amelioration of overactive bladder, irritable bowel syndrome, and the like. This TRPV4 activity inhibitor comprises, as an active ingre...  
WO/2020/071518A1
Provided is a biomarker capable of specifically diagnosing acute renal failure. The acute renal failure-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-5100. Furthermore, it is possible to use this miR...  
WO/2020/071231A1
[Problem] To provide a coated preparation containing stabilized amorphous solifenacin, and a method for stabilizing amorphous solifenacin. [Solution] This solifenacin-containing coated preparation includes: a core containing amorphous so...  
WO/2020/071489A1
The present invention addresses the problem of providing a urothelial cancer biomarker and a method for using the same. This problem is solved by at least one kind of urothelial cancer biomarker selected from the group consisting of clau...  
WO/2020/071258A1
The present invention addresses the problem of providing a composition, etc., that has an exceptional antiglycation function. In particular, the present invention: provides a component that exhibits an antiglycation function against a wi...  
WO/2020/021534A9
The present invention provides stem cells enriched with healthy functional mitochondria, pharmaceutical compositions comprising these cells and methods of use thereof for treating renal diseases, disorders and symptoms thereof where the ...  
WO/2020/071392A1
The present inventor found that, in a cancer disease, cancer cells showing a large expression amount (production amount) of fibrillarin are associated with poor prognosis (a low survival rate). Also, the present inventor found that the p...  
WO/2020/071517A1
Provided is a biomarker capable of specifically diagnosing diabetic nephropathy. The diabetic nephropathy-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-125b-5p and/or miRNA-181b-5p. Furthermore, it i...  
WO/2020/070539A1
The present disclosure provides compositions comprising verinurad, a xanthine oxidase inhibitor, and dapagliflozin useful in the reduction of serum uric acid levels, formulations containing them, and methods using them. In some embodimen...  
WO/2020/071994A1
The present invention relates to the treatment or prevention of oxalate-related disorders, more particularly to the use of a pharmaceutical composition comprising Oxalobacter formigenes in the treatment or prevention of systemic oxalosis...  
WO/2020/064701A1
The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in...  
WO/2020/067333A1
To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts without injuring alveolar epithelial cells and thus inhibits lung fibrosis. A pharmaceutical composition for treating fibrosis that c...  
WO/2020/063976A1
Provided are a fused heterocyclic biaryl benzyl alcohol compound, a preparation method, and use. The fused heterocyclic biaryl benzyl alcohol compound is as represented by formula (IA), has good inhibition activity for a BRD enzyme, and ...  
WO/2020/063463A1
Provided is an application of chiglitazar and related compounds thereof; in vitro models and animal models illustrate that chiglitazar and related compounds thereof inhibit fibroblast activation, matrix production, monocyte activation an...  
WO/2020/063178A1
A gene editing composition or kit used for in vivo gene therapy, comprising: 1) sgRNA that is linked to a nucleic acid molecule of a binding protein and that targets a target mutant gene, or a coding sequence thereof, 2) a template nucle...  
WO/2020/068689A1
Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.  
WO/2020/064597A1
Chronic Kidney Disease (CKD) is a major burden of public health affecting millions of people around the world. It is rising in prevalence with high public health costs and is associated with a high degree of morbidity and mortality. Here...  
WO/2020/066484A1
[Problem] To provide a novel use of ellagic acid. [Solution] The present invention proposes that ellagic acid is usable as an active ingredient of a composition for inhibiting phosphodiesterase-5 activity, a composition for inhibiting th...  
WO/2020/066392A1
The present invention addresses the problem of providing a N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-aza-5α-androst-1 -ene-17β-carboxamide (hereinafter referred to as "compound A")-containing orally administered solid preparation that...  
WO/2020/069498A1
Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the sub...  
WO/2020/061375A1
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram -negative bacteria. Furthermore, the subject compounds and compositions are...  
WO/2020/058424A1
The invention relates to an agent for use in the treatment of patients suffering from systemic inflammatory symptoms and oxidative stress caused by end stage renal disease. Said agent contains a short-chain fatty acid having 3 to 6 carbo...  
WO/2018/226875A3
The present disclosure is directed, among other things, to the surprising and unexpected efficacy provided by select V2R antagonists in significantly reducing the cell proliferation levels of clear cell renal cell carcinoma. Thus, the pr...  
WO/2019/108809A3
Provided herein are nutritional, or therapeutic, compositions and methods of use in primarily treating kidney patients suffering from low serum albumin. The compositions are divided into four formulations, comprising: 1) the magnesium sa...  
WO/2020/059660A1
[Problem] The present invention addresses the problem of providing a novel hENaC αβγ activating agent. [Solution] Provided is a hENaC αβγ activating agent including, as an effective component, a compound or a salt thereof having a ...  
WO/2020/059744A1
Provided is a cancer combination therapy which exhibits an excellent anti-tumor effect and has less side effects by using an acylthiourea compound which is a selective inhibitor of c-Met or a pharmaceutically acceptable salt thereof. Als...  
WO/2020/060986A1
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or ...  
WO/2019/075263A3
Compositions for topical delivery of an active agent and methods for using such compositions are described herein. Compositions include one or more active agents and about 0.001 wt. % to about 10 wt. % of a extracellular matrix component...  
WO/2020/056735A1
A method for improving content of malonyl-ginsenoside in a product, a product containing the malonyl-ginsenoside prepared by the method, and a kit implementing the method. The method comprises the following steps: (1) mixing a sample con...  
WO/2020/054821A1
The present invention addresses the problem of developing, by focusing on the central role of group 2 innate lymphoid cells (ILC2) in the immune system, a drug that is capable of inhibiting the activity of ILC2. The present invention has...  
WO/2019/194772A9
The present invention relates to modified release formulations comprising fesoterodine or a pharmaceutically acceptable salt thereof with at least two sugars or its derivatives as stabilizers.  
WO/2020/054734A1
The purpose of the present invention is to provide a novel pharmaceutical use of a compound A, a pharmaceutically acceptable salt thereof or a monohydrate of the compound A. The present invention relates to a therapeutic or prophylactic ...  
WO/2020/050290A1
The purpose of the present invention is to provide a medicine which contains a small-molecule compound as an active ingredient, and which can exhibit an activity to ameliorate an obesity-related metabolic disease, e.g., an anti-obesity a...  
WO/2020/045838A1
The present invention relates to a composition for preventing or treating prostate disease containing, as active ingredients, extracts from Stauntonia hexaphylla and Cornus officinalis. In particular, the extracts from Stauntonia hexaphy...  
WO/2020/045558A1
The present invention relates to a hydrazinopurine compound or triazolopurine compound represented by the general formula (In the formula: R1, R3, R4, R6, R8, R10, and R12 represent a hydrogen atom or an alkyl group; and R2, R5, R7, R9, ...  
WO/2020/045653A1
The present invention relates to a phytic acid ester derivative and a use of the phytic acid ester derivative. A phytic acid ester derivative according to the present invention has the structure of formula I. [Chemical formula 1] (In for...  
WO/2020/045646A1
The present invention provides a monoclonal antibody having high selectivity and affinity for AGEs, particularly for glyceraldehyde-derived AGEs or glycolaldehyde-derived AGEs, and an analytical method using the same. The present inventi...  
WO/2020/024017A9
The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human sub...  
WO/2020/037853A1
A composition for promoting microcirculation and improving a function of a human body and a preparation method therefor. The composition is made from radix angelicae dahuricae and oyster by extraction and yeast by fermentation, and can t...  
WO/2020/038460A1
Provided by the present invention is a novel quinoline derivative inhibitor, which has a structure represented by the following general formula (I). The compound of the present invention may selectively inhibit the TAM family of tyrosine...  
WO/2020/041680A1
Disclosed are methods of selective glandular pharmaco-ablation using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The methods of selectively destroying prostate gland overgrowth sub...  
WO/2020/039480A1
During research to develop a therapeutic drug for human arthritis using a pentosan polysulfate sodium injection, the present inventors found that the problem of formation of microparticles due to delamination was caused in injection ampo...  
WO/2019/040680A8
Provided herein are methods of treating autoimmune diseases comprising administering to a subject suffering therefrom an immunoproteasome inhibitor and an immunosuppressive agent.  
WO/2020/035040A1
Disclosed are a 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof. Specifically disclosed is a compound or a pharmacologically acceptable salt thereof or a prodrug thereof. The compound has the structure of formu...  
WO/2020/035070A1
A 3-aryloxy-3-aryl-propylamine compound or a pharmaceutically acceptable salt of same, or a prodrug of same, and uses thereof. The compound has the structure of formula I. The compound, the pharmaceutically acceptable salt of same, or th...  
WO/2020/033382A1
Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided alon...  

Matches 401 - 450 out of 50,925